Biogen Media |

All Press Releases

Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference
2/7/17 4:01 pm EST
Biogen Completes Separation of Global Hemophilia Business, Bioverativ
2/1/17 7:30 am EST
Biogen Reports 2016 Revenues of $11.4 Billion
1/26/17 6:30 am EST
Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017
1/17/17 4:01 pm EST
Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
1/17/17 10:42 am EST
Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement
1/17/17 7:30 am EST
New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
1/13/17 7:30 am EST
Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock
1/12/17 8:00 am EST
U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
12/23/16 4:51 pm EST
Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement
12/22/16 4:36 pm EST

Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference
2/7/17 4:01 pm EST
Biogen Completes Separation of Global Hemophilia Business, Bioverativ
2/1/17 7:30 am EST
Biogen Reports 2016 Revenues of $11.4 Billion
1/26/17 6:30 am EST
Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017
1/17/17 4:01 pm EST
Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
1/17/17 10:42 am EST
Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement
1/17/17 7:30 am EST
New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
1/13/17 7:30 am EST
Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock
1/12/17 8:00 am EST
U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy
12/23/16 4:51 pm EST
Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement
12/22/16 4:36 pm EST